Invasive aspergillosis (IA) is a severe fungal infection predominantly affecting immunocompromised individuals or those with critical illnesses. The condition is associated with high morbidity and mortality rates, especially in intensive care unit (ICU) settings, due to delayed diagnosis and limited treatment windows. Effective management of IA requires a structured approach that involves identifying at-risk patients, recognizing clinical and diagnostic clues, and initiating timely antifungal therapy [1, 2] [Ref: Algorithm 102.1].